PDR meta-analysis for the LAC region, 2000–2015.

<p>PDR meta-analysis for the LAC region, 2000–2015.</p

Publications on HIV PDR in the Caribbean, 2000–2015.

<p>Publications on HIV PDR in the Caribbean, 2000–2015.</p

Publications on HIV PDR in Brazil, 2000–2015.

<p>Publications on HIV PDR in Brazil, 2000–2015.</p

Publications on HIV PDR in the Southern Cone, 2000–2015.

<p>Publications on HIV PDR in the Southern Cone, 2000–2015.</p

Publications on HIV PDR in the Mesoamerican Region, 2000–2015.

<p>Publications on HIV PDR in the Mesoamerican Region, 2000–2015.</p

HIV subtype distribution in Brazil.

<p>HIV subtype distributions are shown for the studies included in the meta-analysis by macro-region. No studies were available for the North region. Map obtained from [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0158560#pone.0158560.ref111" target="_blank">111</a>] (public domain).</p

Drug resistance mutation frequency comparison, 2000–2005 vs. 2006–2015, for the Caribbean.

<p>Drug resistance mutation frequency is shown for the studies included in the meta-analysis. Only surveillance mutations included in the WHO list are shown, ordered by drug family. *Significant differences (p<0.05), Fisher’s exact test. NRTI–nucleoside reverse transcriptase inhibitors; NNRTI–non-nucleoside reverse transcriptase inhibitors; PI–protease inhibitors.</p

Drug resistance mutation frequency comparison, 2000–2005 vs. 2006–2015, for the whole LAC region.

<p>Drug resistance mutation frequency is shown for the studies included in the meta-analysis. Only surveillance mutations included in the WHO list are shown, ordered by drug family. *Significant differences (p<0.05), Fisher’s exact test. NRTI–nucleoside reverse transcriptase inhibitors; NNRTI–non-nucleoside reverse transcriptase inhibitors; PI–protease inhibitors.</p

Drug resistance mutation frequency comparison, 2000–2005 vs. 2006–2015, for the Andean region.

<p>Drug resistance mutation frequency is shown for the studies included in the meta-analysis. Only surveillance mutations included in the WHO list are shown, ordered by drug family. *Significant differences (p<0.05), Fisher’s exact test. NRTI–nucleoside reverse transcriptase inhibitors; NNRTI–non-nucleoside reverse transcriptase inhibitors; PI–protease inhibitors.</p